Survival analysis of the HER2+ breast cancer patients showed that the survival time of patients with high expression of CDK12 was significantly lower than that of patients with low expression, with the difference being statistically significant (P = 0.0074) (Fig. 4F). Here, ERBB2 is linked to breast cancer.